Investment Thesis
Precision Biosciences exhibits severe operational deterioration with 50% YoY revenue decline, operating losses of -83.7% margin, and negative free cash flow of -12.0M, indicating a pre-commercial biotech burning significant capital. While the company maintains a strong cash position of 99.4M providing ~8 years of runway, the lack of revenue traction and accelerating losses on a shrinking revenue base suggest failed product development or partnership challenges. Current fundamentals indicate a struggling asset in distress absent meaningful clinical or commercial inflection.
Strengths
- Strong liquidity position with 99.4M cash and 14.02x current ratio
- Conservative leverage with 0.29x debt/equity ratio
- Manageable debt burden of 22.3M relative to equity base of 76.1M
Risks
- Revenue collapse of 50.1% YoY indicates loss of product commercialization or failed partnerships
- Negative free cash flow of -12.0M with deteriorating operating performance suggests escalating burn rate
- Operating margin of -83.7% and net margin of -170.2% show unsustainable unit economics and severe losses
- Declining EPS (-442.3% YoY) with negative ROE (-24.2%) destroys shareholder value
Key Metrics to Watch
- Quarterly revenue trend - stabilization or continued contraction signals viability
- Operating cash burn rate relative to cash runway
- Clinical trial progress or partnership announcements that could restore revenue growth
Financial Metrics
Revenue
10.8M
Net Income
-18.4M
EPS (Diluted)
$-0.75
Free Cash Flow
-12.0M
Total Assets
143.9M
Cash
99.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-83.7%
Net Margin
-170.2%
ROE
-24.2%
ROA
-12.8%
FCF Margin
-110.3%
Balance Sheet & Liquidity
Current Ratio
14.02x
Quick Ratio
14.02x
Debt/Equity
0.29x
Debt/Assets
47.1%
Interest Coverage
-25.64x
Long-term Debt
22.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:43:22.964061 |
Data as of: 2026-03-31 |
Powered by Claude AI